Growth & profitability
- Revenue has grown 27.4% per year over the past 5 years.
- Operating margin has expanded, at -116.9% in the latest year.
BNGO Financials Bionano Genomics, Inc.
9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $29M | -$26M | 46.3% | -116.9% | -59.4% | -35.9% | — | — | $3M |
| 2024 | $31M | -$112M | 1.2% | -337.9% | -316.7% | -146.1% | — | — | $9M |
| 2023 | $36M | -$232M | 26.5% | -596.0% | -241.8% | -108.4% | — | — | $18M |
| 2022 | $28M | -$133M | 21.4% | -473.7% | -53.2% | -43.1% | — | — | $5M |
| 2021 | $18M | -$72M | 21.5% | -428.8% | -21.5% | -19.2% | — | $0 | $25M |
| 2020 | $9M | -$41M | 32.6% | -453.4% | -117.2% | -68.0% | -$38M | $16M | $38M |
| 2019 | $10M | -$30M | 33.2% | -255.4% | -825.2% | -98.7% | -$30M | $20M | $17M |
| 2018 | $12M | -$18M | 27.4% | -170.1% | -182.5% | -74.6% | -$20M | $9M | $17M |
| 2017 | — | -$23M | — | — | 46.5% | -230.3% | -$22M | $7M | $1M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $8M | -$7M | 52.8% | -88.3% | -23.5% | -15.6% | — | — | $4M |
| Mar '26 | $7M | -$8M | 48.6% | -118.1% | -22.2% | -12.8% | — | — | $3M |
| Dec '25 | $8M | -$8M | 42.7% | -107.4% | -17.9% | -10.8% | — | — | $3M |
| Sep '25 | $7M | -$9M | 45.7% | -115.9% | -17.1% | -10.8% | — | — | $3M |
| Jun '25 | $7M | -$7M | 51.6% | -115.8% | -15.1% | -9.0% | — | — | $4M |
| Mar '25 | $6M | -$3M | 45.5% | -131.1% | -6.4% | -4.0% | — | — | $4M |
| Dec '24 | $8M | -$20M | 41.9% | -146.3% | -56.9% | -26.2% | — | — | $9M |
| Sep '24 | $6M | -$44M | -139.1% | -722.9% | -90.5% | -50.6% | — | — | $9M |
| Jun '24 | $8M | -$16M | 33.3% | -219.0% | -20.2% | -12.5% | — | — | $10M |
| Mar '24 | $9M | -$31M | 32.2% | -354.9% | -38.0% | -19.9% | — | — | $16M |
| Dec '23 | $11M | -$44M | 22.7% | -232.7% | -45.6% | -20.5% | — | — | $18M |
| Sep '23 | $9M | -$113M | 29.5% | -1215.0% | -94.6% | -61.9% | — | — | $35M |
| Jun '23 | $9M | -$39M | 26.6% | -453.0% | -18.1% | -14.3% | — | — | $15M |
| Mar '23 | $7M | -$37M | 27.9% | -510.4% | -16.0% | -12.7% | — | — | $4M |
| Dec '22 | $8M | -$39M | 22.0% | -456.8% | -15.5% | -12.6% | — | — | $5M |
| Sep '22 | $7M | -$32M | 25.1% | -445.2% | -11.3% | -9.8% | — | — | $28M |
| Jun '22 | $7M | -$32M | 22.1% | -480.9% | -11.3% | -10.0% | — | — | $27M |
| Mar '22 | $6M | -$30M | 15.1% | -525.7% | -9.6% | -8.6% | — | — | $24M |
| Dec '21 | $6M | -$23M | 3.8% | -456.7% | -6.8% | -6.1% | — | $0 | $25M |
| Sep '21 | $5M | -$21M | 24.8% | -444.2% | -6.1% | -5.8% | -$20M | $0 | $141M |
Valuation over time
How the market has priced BNGO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 263.3× (Mar '23) to 0.5× (Sep '26).
P/S
Frequently asked questions
Is BNGO growing its revenue and profit?
Over the past 5 years, Bionano Genomics, Inc.'s revenue has grown 27.4% per year. These are computed facts, not advice.
How much debt does BNGO have?
As of FY2025, Bionano Genomics, Inc. reported — of total debt against $3M of cash.
What is BNGO's profit margin?
In FY2025, gross margin was 46.3%, operating margin -116.9%, and net margin -92.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.